NCT05796167View on ClinicalTrials.gov

Pimavanserin for Sleep in Parkinson Disease

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 27, 2023

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions
Parkinson Disease
Interventions
DRUG

Pimavanserin

Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks

Trial Locations (1)

11203

SUNY Downstate Health Sciences University, Brooklyn

Sponsors
All Listed Sponsors
collaborator

ACADIA Pharmaceuticals Inc.

INDUSTRY

lead

State University of New York - Downstate Medical Center

OTHER